Open access peer-reviewed chapter

Hurdles in Vaccine Development against Respiratory Syncytial Virus

Written By

Muhammad Shafique, Muhammad Asif Zahoor, Muhammad Imran Arshad, Bilal Aslam, Abu Baker Siddique, Muhammad Hidayat Rasool, Muhammad Usman Qamar and Muhammad Usman

Submitted: 14 November 2018 Reviewed: 29 May 2019 Published: 01 August 2019

DOI: 10.5772/intechopen.87126

From the Edited Volume

The Burden of Respiratory Syncytial Virus Infection in the Young

Edited by Bernhard Resch

Chapter metrics overview

1,565 Chapter Downloads

View Full Metrics


Respiratory syncytial virus (RSV) infection is a major cause of severe respiratory disease in infants and young children worldwide and also forms a serious threat for the elderly. Vaccination could significantly relieve the burden of the RSV disease. However, unfortunately there is no licensed vaccine available so far. This is partly due to disastrous outcome of a clinical trial of formalin-inactivated RSV (FI-RSV) in children in 1960s; leading to enhanced respiratory disease upon natural infection. These findings contributed significantly to the delay of RSV vaccine development. Other key obstacles in development of RSV vaccine such as a peak of severe disease at 2–3 months of age, challenging biochemical behavior of key vaccine antigens and dependence on animal models that may not truly reflect human disease processes. These challenges could be overcome through maternal immunization, structure-based engineering of vaccine antigens, the design of a novel platform for safe infant immunization, and the development of improved animal models. Currently, several vaccine candidates are in pre-clinical and clinical trials targeting the diverse age groups; young children or older adults from the infection or can reduce incidence, mortality and morbidity among the RSV infected individuals.


  • respiratory syncytial virus
  • vaccines
  • adaptive immune response
  • adjuvants
  • animal models
  • infants
  • elderly
  • enhanced respiratory disease
  • innate immune response

1. Introduction

Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory tract diseases among infants, young children and immune-compromised individuals. RSV infection provides partial immunity and reinfection may occur often throughout life. Therefore, RSV infection forms a severe threat in chronically ill adults and the elderly [1]. Current studies have demonstrated that RSV also a main cause of mortality among the elderly, indeed to similar extents as does influenza [2]. Presently, the only approved medication against RSV infection is a prophylactic monoclonal antibody, i.e., Palivizumab, which is given as a prophylaxis to high-risk infants [3]. Despite the isolation and characterization of the virus in 1956, efforts to develop a safe vaccine have been unsuccessful so far. In a clinical trial conducted in young children in the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine did not protect against infection rather led to enhanced respiratory disease (ERD) upon subsequent exposure of the vaccinees to the natural virus. These findings that inactivated RSV vaccines may prime for ERD has contributed significantly to the delay of vaccine development. Other major challenges for development of RSV vaccine are a disease severity at 2–3 months of age, challenging biochemical behavior of key vaccine antigens and dependence on animal models that may not exactly mimic human disease processes. These challenges could be overcome through maternal immunization, structure-based engineering of vaccine antigens, the design of a novel strategy for safe immunization of infants, and the development of better animal models (Table 1).

Target groups Considerations Vaccines approaches
Infants (<6 months) Goal: Prevent severe complications
Challenges: Less developed immune system; more susceptible to disease; FI-RSV enhanced respiratory disease history, maternal Abs present
  1. Live-attenuated vaccines

  2. Gene based vectors

  3. Virus chimeric vectors

Children (6–24 months old) Goal: Prevent severe complications
Challenges: To achieve the clinical end point is not easy; FI-RSV enhanced respiratory disease history
  1. Gene based vectors

  2. Live-attenuated vaccines

  3. Virus chimeric vectors

Elderly people (>65 years) Goal: Po provide protection from infections and complications
Challenges: Lot of previous infections can decrease response to vaccine; necessary to boost up protection provided by natural infection; absence of indicators for severity of disease, diagnosis difficult
  1. Subunit proteins having adjuvant

  2. Gene based vectors having subunit proteins

  3. Vaccines including virus like particles with adjuvants

Pregnant women Goal: To prevent transmission from mother to infants, maximize the protection of infants
Challenges: Lot of previous infections can decrease response to vaccine, necessary to boost up the antibody level for protection of infants
  1. Subunit proteins in combination with standard adjuvants

  2. Vaccines having virus like particles with adjuvants

Table 1.

Key target groups for vaccine candidates.


2. Respiratory syncytial virus

RSV is an enveloped non-segmented negative-sense single-stranded (ss) RNA virus belonging to the Orthopneumovirus genus and Pneumoviridae family [4]. Two serotypes of RSV have been recognized i.e., RSV A and RSV B [4].

The RSV genome comprises 10 genes of 15.2 kb nucleotides encodes 11 proteins [5]. RSV comprises of a nucleocapsid enclosed by a lipid envelope with a diameter of 150–300 nm (Figure 1: RSV particle and RSV-genome). RSV expresses two non-structural proteins such as NS1 and NS2. These are detected only in RSV-infected cells and are not packaged into the virion. They mainly serve to inhibit type I interferon responses [7]. Eight RSV proteins are present in the virion particles. Among these structural proteins, three are membrane proteins: the attachment protein G, the fusion protein F and the small hydrophobic protein (SH). The heavily glycosylated G protein is responsible for viral attachment to the cell. The F protein not only contributes to binding of the virus to cells, but also plays a crucial part during entry of virus by mediating fusion of the viral envelope with the cell membrane, thereby allowing deposition of the viral genome into the cytosol [8]. Besides this, F protein is a mediator of syncytium formation [5]. The function of the SH protein, which is mostly found in the infected-cell membrane, is unknown [9]. Other viral structural proteins are the nucleocapsid protein (N), the matrix protein (M), the phosphoprotein (P), the RNA-dependent RNA polymerase (L) and the M2 gene product M2-1: all these proteins are located inside the viral particle. Whereas the M2-2 gene product is packaged in the virion is currently unknown [10]. The function of the matrix (M) protein is to connect the viral nucleocapsid with the lipid envelops and it is also responsible for viral particle assembly. The M2-2 protein is involved in regulation of viral transcription [11]. M2-1 functions as transcription-elongation factor [12]. The phosphoprotein (P) and nucleocapsid protein (N) are essential for transcriptional activity, while the L protein has RNA polymerase activity.

Figure 1.

Schematic representation of the RSV virion and its genome composition (adapted and modified with permission from [6]).


3. Epidemiology

RSV infections have a distribution worldwide. These infections are more common during the winter season in temperate climates. However, RSV infections may occur throughout the year in tropical climates, but can be more frequent in the monsoon season in some areas [13, 14, 15]. Although infection can be established in several laboratory animals, however, natural infection with RSV appears to be limited to apes and humans [16]. RSV transmission occurs via direct contact or contact with contaminated surfaces that harbor respiratory secretions. The virus can survive for many hours on toys or other substances, which explains the high rate of nosocomial RSV infections particularly in pediatric wards. The incubation period for RSV infection ranges between 2 and 7 days [17]. Almost 70% of newborns are infected in the first year of their life. By the age of 2 years, almost all children have been infected and over 50% will have been infected twice [18]. RSV infections are common in the population and re-infections probably occur frequently. In a study conducted by Hall et al., 1991, almost 25% of adult volunteers could be re-infected with RSV of the same group, 2 months after a natural infection [19].

RSV infection is the major source of severe respiratory illness in infants and young children and is the most frequent cause of hospitalization of infants and young children in industrialized countries [20]. RSV infections differ in disease severity, from a mild cold to bronchiolitis or pneumonia. Almost 3% of infants infected with RSV need hospitalization due to respiratory failure and feeding problems [21]. Among the hospitalized infants, 20% need mechanical ventilation [22]. The highest morbidity of RSV disease is seen in children under the age of 6 months [23] and in children with associated risk factors such as prematurity, broncho-pulmonary dysplasia, congenital heart disease with increased pulmonary circulation or immune deficiency [24, 25, 26, 27]. According to WHO estimates, RSV disease burden is ~64 million cases and 160,000 deaths per year worldwide. In USA, about 85,000–144,000 infants are admitted to hospitals with RSV infection annually which corresponds to 20–25% of pneumonia cases and about 70% bronchiolitis cases in the hospital [28, 29]. The elderly people are also at risk for extreme RSV disease and almost 14,000–62,000 RSV-associated hospitalizations of the elderly occur in USA with an approximate annual cost of RSV pneumonia-related hospitalizations of $150–680 million [30, 31].


4. Pathogenesis

After RSV infection, virus primarily multiplies in the epithelial cells of the nasopharynx [32]. The exact mechanism by which RSV spreads to the lower respiratory tract is not clear yet. Currently, it is not known why the disease progression is mild in most children, but severe in a small subgroup. Different studies have described associations between disease severity and genes involved in allergic responses, like IL-4 and IL-4 receptor genes, and genes for inflammatory cytokines, e.g., IL-6 and IL-8 [33]. Furthermore, up-regulation of chemokines during RSV infection is associated with disease severity. For example, CCL11 (eotaxin), RANTES (CCL5) and MIP1α have been found in higher levels in cases with more severe RSV infection and ERD [34, 35].

Several other factors could be associated with disease severity, for example, environmental factors, patient intrinsic factors, virus strain and viral load. Environmental factors like a high number of siblings, attendance of day-care centers and socio-economic status can enhance the chance of early exposure and may increase the risk of developing lower respiratory tract disease [36]. Other factors like geographical area, parental smoking and the use of wood-burning stoves have also been linked to an enhanced risk of severe RSV infections [37, 38, 39, 40]. Patient-intrinsic factors like a compromised respiratory function, e.g., bronchopulmonary dysplasia (BPD) [25], or congenital heart disease with increased pulmonary circulation may significantly enhance the risk to develop severe RSV infection [41]. It is reported in some studies that RSV-strain A is responsible for more severe disease [42], while other studies report no difference between RSV A and B strains [43, 44]. Furthermore, the course of lower respiratory disease was found to be associated with a high viral load [45]. Finally, RSV-specific immunity induced by vaccination may also be involved in immunopathological mechanisms leading to enhanced disease. This hypothesis is mainly based on experimental animal data [46], and on observations from a clinical trial where, as indicated above, infants were vaccinated with FI-RSV vaccine, which resulted in enhanced respiratory disease (ERD) upon natural infection [47, 48, 49]. The notion that inactivated-RSV preparations can prime for ERD is one of the factors that has delayed the development of an effective RSV vaccine.


5. Therapeutic approaches against RSV

Only supportive treatment is available. In supportive treatment we can use corticosteroids, bronchodilator and oxygen supplement. These are effective to some extent [50]. It is viral infection, so the use of antibiotics is not recommended, but according to some studies antibiotics can be used to some extent but not regularly to prevent the secondary bacterial infection such as urinary tract infections [51]. Corticosteroids also cannot be used routinely because they are the immunosuppressors [52]. The only recommended antiviral RSV treatment at clinical level is ribavirin. Studies are present which indicate the conflicting results of ribavirin use. It is also less effective and very costly. Due to the conflicting results of ribavirin, American Academy of Science recommendation is that ribavirin should not be routinely used in children having the symptoms of bronchiolitis [53]. Ribavirin completes its function by preventing the polymerase of virus. So ribavirin can inhibit both the DNA and RNA viruses. Ribavirin action may result in anemia and other adverse reactions such as hypersensitivity. According to few studies, ophthalmologic disorders also have been noted after the use of ribavirin. All these side-effects lead towards the limited use of ribavirin in RSV treatment [54]. A study indicated that ribavirin might be used in target groups such as children having RSV infection with comorbid immunosuppression, but it is necessary to investigate and verify more data about its recommendation [55, 56]. It has also been noted that once the disease has occurred, no effective treatment is available for preventing the disease. Another study explained its failure in treatment describing that inhibiting the replication of virus alone is not enough to block the virus mediated pathogenesis in host. So, due to limited treatment options and high disease burden, it is necessary to discover the new treatment as well as prophylactic policies.

Now there is focus on F protein for the development of anti-RSV drugs as well as vaccines. Researches are being conducted for the development of numerous antiviral drugs and antibodies that are in preclinical development stage. Some of the new vaccine and drugs are in evaluation stage. Experiments were conducted on cotton rats and mice in which RSV F specific nano-bodies and immunoglobulin were administered by intranasal route. This led to reduction in lung inflammation and also decreased the virus replication after RSV infection [57]. The RSV G protein is also being targeted for the development of drugs, prophylactic agents and vaccines. The RSV G protein consists of CX3C motif and is homologous in structure with CX3CL1 [58]. RSV G protein increases the infection rate by binding the receptor CX3CR1. Experiments have shown that anti- RSV G monoclonal antibodies have the ability to block the interaction between RSV G CX3C-CX3CR1. This interaction inhibition decreased the lung inflammation. Experiments conducted on rats also have been shown that RSV G monoclonal antibodies have the greater ability to decrease the pulmonary inflammation when compared with anti-F monoclonal antibodies [59, 60, 61].


6. Current status of RSV vaccine

At present, there is no approved vaccine is present in the market which can protect from RSV infection. Due to increased burden of disease, it is essential to develop a vaccine that can give protection against the disease [47]. Recently, a lot of RSV vaccine candidates have been emerged using a variety of advanced technologies. About 60 RSV vaccines candidates targeting the pediatric and older populations are in development stage and some are also in preclinical stage [62]. According to a study, 16 RSV vaccine candidates are in clinical development stage [62].

6.1 Live attenuated vaccine

During 1960s, after the failure of formalin inactivated RSV vaccine (FI-RSV), struggles were started to develop live-attenuated vaccines candidates. By serial passaging of RSV A2 strain at lower temperature, live attenuated vaccines were produced; however, it was hard to achieve the balance between immunogenicity and safety [62].

Today, a lot of the cold passage (cp) and temperature sensitive (ts) vaccines have been produced. Evaluation of one cpts-248/404 was done in 1–2 month old aged infants. But it led to the problem such as congestion of upper respiratory tract and so, it was not followed for more investigations. After this struggles were done to attenuate the cpts-248/404 strain and many mutants were produced. After evaluation these generated mutants were found to be over or under attenuated [63].

There is another live-attenuated type RSV vaccine which includes M-2 gene deletion is being tested on nonhuman primates. The M-2 gene regulates the transition from transcription to RNA replication. Studies have shown that by the deletion of M-2 gene, viral RNA replication is decreased but at the same time G and F protein expression is increased through transcription which means that virus is attenuated at adequate level and may lead to neutralizing antibody response [64].

NS2 is another target gene for producing live attenuated vaccine RSV NS2. gene increases the shedding of epithelial cells and reduces or inhibits the antiviral cellular type 1 IFN induction and IFN response of the host. Vaccines which include the deletion of NS2 gene are stable genetically and sensitive to temperature to some extent [65, 66]. SH gene also has been considered for deletion for the live attenuated vaccines. It is believed that SH gene is involved in viral fusion. According to few studies, it is involved in the inhibition of apoptosis by blocking the TNF- alpha pathway. To obtain the sufficient attenuation level to get the safety is the major continuing problem for live attenuated RSV vaccine [65, 66, 67].

6.2 Subunit vaccines

RSV G and F glycoproteins lead to the induction of neutralizing antibodies. These have been evaluated as potential vaccine candidate [68]. Subunit vaccines have the potential to be used for maternal immunization. They are also useful candidates for elderly immunization. A number of subunit vaccines have been evaluated recently. The vaccines which are in clinical trials are co-purified G, F and M proteins; purified F glycoprotein (PFP-1, PFP-2 and PFP-3); and BBG2NA etc. [69, 70, 71, 72, 73, 74, 75, 76].

RSV PFP-1, PFP-2 and PFP-3 are the candidates which have been evaluated in children of >12 months of age and also in elderly target populations. These vaccine candidates consist of purified glycoprotein which are adsorbed to Al(OH)3 (PFP-1 and PFP-2) or AlPO4 (PFP-3). These candidates were sufficiently tolerated by the target populations but acute reactions were also observed up-to minimum level. There was no observation of enhanced disease occurrence [70, 71, 72, 73, 74, 75, 76, 77].


7. Challenges to RSV vaccine development

7.1 Early age when immature immune system of neonates

The most noteworthy risk group for extreme RSV infection is infants under a half year of age [78, 79]. Practically speaking, first dose should be administered at the age of 2 months. Full term newborn children obtain maternal antibodies during the latter 50% of gestation and levels of antibody remain moderately high for a half year after the birth [80]. This would interfere when RSV vaccine would be done [81]. So there is need of an ideal vaccine which will not interfere with the maternal antibodies and will give protection in the presence of maternal antibodies. A few investigations show that newborn children under the age of 8 months have a less serum counter acting agent (antibody) response to characteristic RSV disease as compared to elder ones [82]. A less developed immune system may be the reason of this reduced immunity level, but maternal antibodies may also suppress the immune response [83].

Recent schedule for hepatitis B, diphtheria, rotavirus, pneumococcus, pertussis, tetanus, Haemophilus influenzae type b and poliovirus show that vaccine for these infectious diseases will be done ideally after birth at 2, 4 and 6 months of age. Vaccination for RSV should be ideally administered at 6 months of age, so it is necessary and important to make sure that RSV vaccine should not interfere the working and efficacy of other routinely used vaccines during the childhood [84].

7.2 Induction of low affinity neutralizing antibodies

RSV vaccine was developed shortly after it was isolated. In 1960, FI-RSV vaccine was injected by intramuscular route in 2–7 months old infants and children. Instead of providing protection against wild type RSV infection, FI-RSV enhanced the respiratory disease development following wild type RSV infection during the subsequent RSV season. Lungs of children and infants with enhanced diseased were rich with large numbers of eosinophils and this was not found in patients of natural infection with RSV. After this disastrous outcome, there was need to develop a safe RSV vaccine including the evaluation of enhanced disease [47, 48, 49, 85, 86].

These different immunopathology aspects which were seen in humans after FI-RSV vaccine and enhanced disease were later studied in non-human primates. In newborn macaques which were FI-RSV vaccinated and then infected with RSV virus, enhanced disease with increased level of eosinophils and neutrophils were seen [87, 88, 89, 90, 91]. FI-RSV produced the increased level of ELISA titer RSV antibody because it was highly immunogenic, but the provoked antibodies were non-neutralizing. Antibodies produced did not provide the protection against virus because it could not prevent the fusion of virus [92, 93]. FI-RSV induced resulted RSV antibodies were also known to be of decreased avidity and this may be the result of having lack of maturation [94, 95, 96, 97].

7.3 Lack of appropriate animal models

No ideal animal model for RSV vaccine is present which can be used for its evaluation. African green monkey kidney cells (Vero cells) were used for production of RSV. High titers of RSV were observed on Vero cell line. Similar results were obtained when grown on human cells (HEp-2). On both these cell lines, RSV infection led to syncytia formation. These cell lines were used extensively to characterize the live attenuated RSV vaccines. In recent studies, there are reports that NHBE (normal human bronchial epithelial) and HAE (human airway epithelial) cells are used to create model human nasopharyngeal mucosa. RSV infection did not show any pathological sign and also not led to syncytia formation on NHBE and HAE cell lines [98, 99].

Experiments to study attenuation of live attenuated RSV vaccine were also conducted on BALB/c mice, found permissive to infection to some extent. Advantages for mouse studies are that reagents are readily available which can be used for measurement of infection immune correlates [99, 100, 101, 102, 103, 104]. Several non-human primates act as host for RSV. RSV can replicate in the nasopharyngeal tract of their host. Macaques, African green monkeys, Chimpanzees and bonnet monkeys have been used to model RSV infection [105, 106, 107, 108, 109, 110, 111, 112]. Relative viral titers of live attenuated RSV vaccines compared to wild type RSV disease can also be measured. Chimpanzees are the only non-human hosts which develop and show the clinical sign and symptoms of coryza following RSV infection. They are much permissive to RSV infection. So they are used for evaluation of comparative level of attenuation among vaccines which are candidates in humans. But it has been shown by the recent studies that chimpanzee is not completely predictive of attenuation in young newborns. They are also scare and expensive. Study conducted by Karron et al. showed that those RSV vaccines sensitive to temperature and also had high degree attenuation in chimpanzee, were able to produce infection in lower respiratory tract in children [112].

7.4 Absence of RSV disease liability data and commercial risk

It is known that those children and persons primed with RSV are not at risk to RSV enhanced illness, but the absence of enhanced disease illness in RSV primed persons does not support the prediction that it will not be present in RSV naïve population. So it is very difficult to build up safety data which can support and be used for testation of novel RSV vaccine in newborns having age <6 month which is primary target population [113, 114]. There is absence of information (data) on RSV related mortality. This has prevented exact appraisal of the expenses and advantages of RSV vaccines and prioritization of vaccines for various target populaces [49]. Lack of information on disease liability data is a big problem in less developed countries where mortality cases are concentrated [115].

7.5 Limited resources

Clinical investigations of applicant vaccines in the target populace are fundamental to figure out which vaccines ought to be created for licensure, yet these examinations are tedious and costly, what’s more, assets for these investigations are restricted. Measurement of impact of vaccine on disease in all target populations is very difficult and problematic. It is easy to diagnose RSV infection in infants and children because their respiratory secretions have high titers of RSV and so are easy to detect. Titers of virus in adults are low and sensitive RT-PCR assay is used for detection purpose. If there is a decrease in severity of disease, it is a good indication of vaccine being effective. Measures done for disease severity are not accurate at all ages of target populations. So there is need that larger and most costly studies should be performed [116].

7.6 Emerging RSV variants/mutation in RSV genome

RSV is divided antigenically into two groups which are RSV-A and RSV-B. These groups are further divided into genotypes as well as variants. It has been investigated that different viruses belong to these different groups; genotypes as well as variants co-circulate in epidemics. So it is very difficult to develop an effective vaccine due to the presence of virus antigenic diversity as well as variability. Like other RNA viruses, RSV has high nucleotide substitution rate (10−3–10−4). Spontaneous type of deletions of G and SH genes have been studied in vitro. RSV genome encodes 11 proteins; one of them is G protein which is most variable having 2 hypervariable regions. G protein has been investigated to accumulate amino acid changes periodically. RSV genotypes having the amino acids duplications in G proteins also have been isolated.

7.7 Disruption of antigenic epitopes

Researches had shown that formalin inactivation caused the alterations in the epitopes of the G and F proteins and as a result non-neutralizing antibodies were developed which led to formation of immune complex in the lungs [57, 69]. Recent studies have shown that changes in the properties of F protein occur during interaction of virus and host cell. The pre fusion (pre-F) which is highly energetic, transitions irreversibly into post fusion (post-F) form which is low energetic and stable, this occurs during insertion process of virus into host cell membrane. By this process, fusion of virus to host occurs. Although pre and post F are not structurally similar, they share 2 antigenic regions. Neutralizing antibodies target these antigenic regions. Pre F also has 3 other antigenic sites not present in post-F. These sites are neutralization sensitive [68, 69, 70, 71, 72]. It is investigated that pre-F conformation changes to post-F conformation during the mechanism of formalin as well as heat inactivation and this change is irreversible. As a result of this change, complete loss of epitopes occurs. So this process explains the one of the reasons for failure of FI-RSV [69, 71].

7.8 Older age when immune-senescence of the elderly people

Elder target population group possess a considerable disease burden. The elder group has preexisting immunity, which makes it inconvenient to increase the existing immunity. Furthermore immune-senescence may lead to decrease in the efficacy of vaccine [116]. Immune-senescence is a challenge for proper vaccination in older target populations. RSV disease burden increases in elderly people in presence of underlying diseases such as cardiac and pulmonary conditions. Live attenuated vaccines are found not to be immunogenic in elderly people. So now focus is on subunit vaccines for this target group [115, 117].


8. Future horizons in RSV vaccine and RSV therapeutics

  • Continuous struggles are going on for the development of effective and safe RSV vaccines for each target group (infants, children, elders including pregnant women). Previous struggles made to build up a safe vaccine were failed. High antibody production was seen by the use of FI-RSV vaccine in 1960. However, unfortunately vaccinated children developed a severe disease after administration of FI-RSV vaccine. Difficulties and barriers associated with vaccine development particularly live attenuated vaccine are enhanced respiratory disease, maternal antibodies, nasal congestion, low immunogenicity, genetic variability and instability, immature immune system of infants, vaccine virus transmission and immune-senescence as well as preexisting immunity in elders. However, these problems are being slowly overcome [118].

  • Major achievements in last 3 years are that nanoparticle based vaccines and live vector vaccines have been investigated in different phase 1 and phase 2 trials and efficient results obtained. These vaccines step forward into later phase trials for evaluation [119]. So, there is hope that safe and well tolerated vaccine candidates will provide a long lasting immunity to all target groups, may be in our hands with in ~5–10 years.

  • In vitro tissue culture system has been developed, that are being used for predicting the efficacy and safety of candidate vaccines.

  • Palivizumab is only the success which is available to clinicians and is being used to reduce the burden of RSV. Palivizumab has decreased hospitalization; however, its use is limited due to high cost. There is hope that this approved prophylactic approach will be available to everyone and may soon come into extensive and widespread use. Palivizumab is patent of MedImmune and this patent is near to expire. So with expiry of this patent, there is hope that a cost effective palivizumab version will be developed. A recent technology hub has been established by the World Health Organization (WHO), the purpose of this is to increase the production of biosimilar versions [120]. There is hope that these products will be available in the market at low and affordable cost. These good initiatives will greatly reduce the mortality rates caused by RSV in developing world.

  • Oral antivirals such as GS-5806 and a nucleoside analogue ALS-008176 have been passed through trials and they significantly decreased the replication of virus in human controlled experiments [121]. Nanobodies (single domain antibodies) has also been developed that protected the mice from infection and now are ready for clinical development. These results renewed the hope that an effective antiviral treatment for different risk populace will be on the horizon in next few years [57].


9. Conclusions

One of the most common causes of the respiratory tract diseases is the RSV affecting infants, young children and the elderly people. Only supportive treatment is available such as corticosteroids, bronchodilators, oxygen supplement and ribavirin etc. which may not be occasionally effective. Palivizumab has decreased hospitalization; however, its use is limited due to high cost. Despite it is the era of progress and technology, no RSV licensed vaccine is available in the market to prevent RSV infection. Natural infection also provides partial immunity. A successful vaccine candidate will provide the long term protective immunity and must not lead to induction of enhanced RSV disease. For RSV vaccine development different target groups are being considered such as elders including pregnant women, children and infants. Each of these target groups has different challenges for vaccine development. Maternal antibodies, enhanced disease and immature immune system are the major barriers for vaccine development in the infants. The children >6 months of age have more mature immune system than infants but still can be at the risk of enhanced disease from non-live RSV vaccine. For elderly target population immune-senescence as well as pre-existing immunity is the barrier for vaccine development.

An ideal RSV vaccine should be safe, well tolerated and provide long lasting immunity as compared to natural infection against both RSV strains A and B. Further, it is recommended that separate vaccines should be developed for each target group. The tools that ought to enable us to build up a sheltered and successful RSV vaccine are accessible and our challenge is to utilize them wisely. We trust the suggestions for vaccine advancement noted above can support researchers, subsidizing offices, and industry center their endeavors and assets most productively and viably.


Conflict of interest

There is no potential conflict of interest among the authors listed in this manuscript.


  1. 1. Dowell SF, Anderson LJ, Gary HE Jr, Erdman DD, Plouffe JF, File TM Jr, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. The Journal of Infectious Diseases. 1996;174(3):456-462
  2. 2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. The New England Journal of Medicine. 2005;352(17):1749-1759
  3. 3. Null DM, Bimle C, Weisman LE, Johnson K, Steichen J, Singh S, et al. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531-537
  4. 4. Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection. International Journal of Molecular Sciences. 2017;18(8):pii.E1717. DOI: 10.3390/ijms18081717
  5. 5. Hacking D, Hull J. Respiratory syncytial virus—Viral biology and the host response. The Journal of Infection. 2002;45(1):18-24
  6. 6. Shafique M, Rasool MH, Khurshid M. Respiratory syncytial virus: An overview of infection biology and vaccination strategies. Future Virology. 2017;12(5):297-313
  7. 7. Spann KM, Tran KC, Collins PL Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. Journal of Virology. 2005;79(9):5353-5362
  8. 8. Feldman SA, Audet S, Beeler JA. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. Journal of Virology. 2000;74(14):6442-6447
  9. 9. Feldman SA, Crim RL, Audet SA, Beeler JA. Human respiratory syncytial virus surface glycoproteins F, G and SH form an oligomeric complex. Archives of Virology. 2001;146(12):2369-2383
  10. 10. Gonzalez PA, Bueno SM, Carreno LJ, Riedel CA, Kalergis AM. Respiratory syncytial virus infection and immunity. Reviews in Medical Virology. 2012;22(4):230-244
  11. 11. Cheng X, Park H, Zhou H, Jin H. Overexpression of the M2-2 protein of respiratory syncytial virus inhibits viral replication. Journal of Virology. 2005;79(22):13943-13952
  12. 12. Fearns R, Collins PL. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. Journal of Virology. 1999;73(7):5852-5864
  13. 13. Spence L, Barratt N. Respiratory syncytial virus associated with acute respiratory infections in Trinidadian patients. American Journal of Epidemiology. 1968;88(2):257-266
  14. 14. Huq F, Rahman M, Nahar N, Alam A, Haque M, Sack DA, et al. Acute lower respiratory tract infection due to virus among hospitalized children in Dhaka, Bangladesh. Reviews of Infectious Diseases. 1990;12(Suppl 8):S982-S987
  15. 15. Vardas E, Blaauw D, McAnerney J. The epidemiology of respiratory syncytial virus (RSV) infections in South African children. South African Medical Journal. 1999;89(10):1079-1084
  16. 16. Byrd LG, Prince GA. Animal models of respiratory syncytial virus infection. Clinical Infectious Diseases. 1997;25(6):1363-1368
  17. 17. Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. The Journal of Pediatrics. 1981;99(1):100-103
  18. 18. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. The New England Journal of Medicine. 1979;300(10):530-534
  19. 19. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. The Journal of Infectious Diseases. 1991;163(4):693-698
  20. 20. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. The Journal of Infectious Diseases. 1997;175(4):807-813
  21. 21. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446
  22. 22. Tissing WJ, van Steensel-Moll HA, Offringa M. Risk factors for mechanical ventilation in respiratory syncytial virus infection. European Journal of Pediatrics. 1993;152(2):125-127
  23. 23. Green M, Brayer AF, Schenkman KA, Wald ER. Duration of hospitalization in previously well infants with respiratory syncytial virus infection. The Pediatric Infectious Disease Journal. 1989;8(9):601-605
  24. 24. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. The Journal of Pediatrics. 1992;121(3):348-354
  25. 25. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988;82(2):199-203
  26. 26. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. The New England Journal of Medicine. 1982;307(7):397-400
  27. 27. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, et al. Respiratory syncytial viral infection in children with compromised immune function. The New England Journal of Medicine. 1986;315(2):77-81
  28. 28. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. The Journal of Pediatrics. 2003;143(5 Suppl):S112-S117
  29. 29. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clinical Infectious Diseases. 2001;33(6):792-796
  30. 30. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. The Journal of Infectious Diseases. 1999;179(1):25-30
  31. 31. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clinical Microbiology Reviews. 2000;13(3):371-384
  32. 32. Hall WJ, Hall CB, Speers DM. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Annals of Internal Medicine. 1978;88(2):203-205
  33. 33. Miyairi I, DeVincenzo JP. Human genetic factors and respiratory syncytial virus disease severity. Clinical Microbiology Reviews. 2008;21(4):686-703
  34. 34. Culley FJ, Pennycook AM, Tregoning JS, Hussell T, Openshaw PJ. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. Journal of Virology. 2006;80(9):4521-4527
  35. 35. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. The Journal of Infectious Diseases. 2001;184(4):393-399
  36. 36. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. American Journal of Epidemiology. 1973;98(4):289-300
  37. 37. Brandenburg AH, Jeannet PY, Steensel-Moll HA, Ott A, Rothbarth PH, Wunderli W, et al. Local variability in respiratory syncytial virus disease severity. Archives of Disease in Childhood. 1997;77(5):410-414
  38. 38. Singleton RJ, Petersen KM, Berner JE, Schulte E, Chiu K, Lilly CM, et al. Hospitalizations for respiratory syncytial virus infection in Alaska Native children. The Pediatric Infectious Disease Journal. 1995;14(1):26-30
  39. 39. McConnochie KM, Roghmann KJ. Breast feeding and maternal smoking as predictors of wheezing in children age 6 to 10 years. Pediatric Pulmonology. 1986;2(5):260-268
  40. 40. Wright AL, Holberg C, Martinez FD, Taussig LM. Relationship of parental smoking to wheezing and nonwheezing lower respiratory tract illnesses in infancy. Group Health Medical Associates. The Journal of Pediatrics. 1991;118(2):207-214
  41. 41. Jung JW. Respiratory syncytial virus infection in children with congenital heart disease: Global data and interim results of Korean RSV-CHD survey. Korean Journal of Pediatrics. 2011;54(5):192-196
  42. 42. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. The Journal of Infectious Diseases. 1997;175(4):814-820
  43. 43. Hornsleth A, Klug B, Nir M, Johansen J, Hansen KS, Christensen LS, et al. Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions. The Pediatric Infectious Disease Journal. 1998;17(12):1114-1121
  44. 44. Devincenzo JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: A study of frequency, disease severity, and viral load. Pediatric Research. 2004;56(6):914-917
  45. 45. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. The Journal of Infectious Diseases. 2005;191(11):1861-1868
  46. 46. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J. Immunopathology of RSV infection: Prospects for developing vaccines without this complication. Reviews in Medical Virology. 2007;17(1):5-34
  47. 47. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology. 1969;89(4):422-434
  48. 48. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. American Journal of Epidemiology. 1969;89(4):435-448
  49. 49. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. American Journal of Epidemiology. 1969;89(4):449-463
  50. 50. Roymans D, Koul A. Treatment of respiratory syncytial virus infection: Past, present and future. In: Resch B, editor. Human Respiratory Syncytial Virus Infection. Rijeka, Croatia: In Tech; 2011. pp. 197-215
  51. 51. Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database of Systematic Reviews. 2008;1:CD004878
  52. 52. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Bronchodilators for bronchiolitis. Cochrane Database of Systematic Reviews. 2006;3:CD001266
  53. 53. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database of Systematic Reviews. 2007;1:CD000181
  54. 54. Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing developments in RSV prophylaxis: A clinician’s analysis. Current Opinion in Virology. 2017;24:70-78
  55. 55. Dawson-Caswell M, Muncie HL Jr. Respiratory syncytial virus infection in children. American Family Physician. 2011;83(2):141-146
  56. 56. Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: Current and emerging treatment options. ClinicoEconomics and Outcomes Research. 2014;6:217-225
  57. 57. Schepens B, Ibañez LI, De Baets S, et al. Nanobodies specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. The Journal of Infectious Diseases. 2011;204:1692-1701
  58. 58. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature Immunology. 2001;2:732-738
  59. 59. Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. The Journal of Infectious Diseases. 2009;200:439-447
  60. 60. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy. 2010;2:655-661
  61. 61. Caidi H, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM. The effects of combination therapy using monoclonal antibodies against RSV G glycoprotein in BALB/c mice. PLoS ONE. 2012;7:e51485
  62. 62. Deboarh H, Carrie T, Cheryl K. Advances in RSV vaccine research and development: A global agenda. Vaccine. 2016;34:2870-2875
  63. 63. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine. 2000;18:1763-1772
  64. 64. Teng MN, Whitehead SS, Bermingham A, et al. Recombinant respiratory syncytial virus that does not express the NS1or M2-2 protein is highly attenuated and immunogenic in chimpanzees. Journal of Virology. 2000;74:9317-9321
  65. 65. Luongo C, Winter CC, Collins PL, Buchholz UJ. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. Journal of Virology. 2013;87:1985-1996
  66. 66. Liesman RM, Buchholz UJ, Luongo CL, Yang L, Proia AD, DeVincenzo JP, et al. RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction. The Journal of Clinical Investigation. 2014;124:2219-2233
  67. 67. Cunningham CK. R. A Phase I study of the safety and immunogenicity of a single dose of the recombinant live attenuated respiratory syncytial virus vaccine RSV cps2, Lot RSV#005A, Delivered as nose drops to RSV-seronegative infants and children 6 to 24 months of age. Edited by: Regulatory compliance and human subjects protection branch (RCHSPB), Division of clinical research (DCR)/Office of the director (OD), The national institute of allergy and infectious diseases (NIAID), The eunice kennedy shriver national institute of child health and Human development (NICHD); 2013. pp. 10-20
  68. 68. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields Virology. 4th ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 1443-1485
  69. 69. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP 2) in ambulatory adults over age 60. Vaccine. 1996;14:1214-1218
  70. 70. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine. 1997;15:1130-1132
  71. 71. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: Clinical and immune responses to subsequent natural infection in children. The Journal of Infectious Diseases. 1993;168:1024-1029
  72. 72. Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. The Pediatric Infectious Disease Journal. 1994;13:792-798
  73. 73. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. The Journal of Infectious Diseases. 1993;167:191-195
  74. 74. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. The Pediatric Infectious Disease Journal. 1996;15:23-31
  75. 75. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. The Journal of Infectious Diseases. 1998;177:467-469
  76. 76. Munoz FM, Piedra PA, Maccato M, Kozinetz C, Glezen WP. Respiratory syncytial virus purified fusion protein-2 (RSV-PFP-2) vaccine in pregnancy [abstract]. In: RSV After 45 Years. Segovia, Spain: Instituto de Salud Carlos, Ministerio de Sanidad y Consumo; 2001. p. 45
  77. 77. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 1997;230:155-166
  78. 78. Lee M-S, Walker RE, Mendelman PM. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children, implications for design of vaccine trials. Human Vaccines. 2005;1:6-11
  79. 79. Karron RA, Singelton RJ, Bulkow L, Parkinson A, Kruse D, De Smet I, et al. Severe respiratory syncytial virus disease in Alaska native children. The Journal of Infectious Diseases. 1999;180:41-49
  80. 80. Brandenburg AH, Groen J, van Steensel-Moll HA, Claas ECJ, Rothbarth PH, Neijens HJ, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. Journal of Medical Virology. 1997;52:97-104
  81. 81. Groothuis JR, Simoes E, Myron JL, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The New England Journal of Medicine. 1993;329:1524-1530
  82. 82. Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 0-6 years. United States: 2008;
  83. 83. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. The New England Journal of Medicine. 2009;360:588-598
  84. 84. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet. 2010;375:1545-1555
  85. 85. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RSV virus vaccine. American Journal of Epidemiology. 1969;89:405-421
  86. 86. Kim HW, Arrobio JO, Pyles G, Brandt CD, Camargo E, Chanock RM, et al. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics. 1971;48:745-755
  87. 87. Prince GA, Jensen BA, Hemming VG. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. Journal of Virology. 1986;57:721-728
  88. 88. De Swart RL, Kuiken T, Timmerman HH, Van Amerongen G, Van Den Hoogen BG, Vos HW, et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. Journal of Virology. 2002;76:11561-11569
  89. 89. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. The Journal of Experimental Medicine. 2002;196:859-865
  90. 90. Polack FR. A typical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatric Research. 2007;62:111-115
  91. 91. Waris ME, Tsou C, Erdman DD, Zaki WR, Anderson LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhance pulmonary inflammatory response with a predominant Th2-like cytokine pattern. Journal of Virology. 1996;70:2852-2860
  92. 92. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. Journal of Clinical Microbiology. 1988;26:1595-1597
  93. 93. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau Q  J, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine. 2006;12:905-907
  94. 94. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Medicine. 2008;15:34-41
  95. 95. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007;25:7372-7378
  96. 96. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: Applications of reverse genetic. The Journal of Clinical Investigation. 2002;110:21-27
  97. 97. Murphy BR, Hall SL, Kulkarni AB, Crowe JE Jr, Collins PL, Connors M, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research. 1994;32:13-36
  98. 98. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. Journal of Virology. 2005;79:8651-8654
  99. 99. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. Journal of Virology. 2002;76:5654-5666
  100. 100. Jafri HS, Chavez-Bueno S, Mejias A, Rios AM, Shahryar SN, Usuf M, et al. Respiratory syncytial virus lower respiratory tract infection induces acute pneumonia, cytokine response, airway obstruction and chronic inflammatory infiltrates associated with longterm airway hyper-responsiveness in mice. The Journal of Infectious Diseases. 2004;189:1856-1865
  101. 101. Mejais A, Cavez-Bueno S, Rios AM, Saavedra-Lozano J, Aten MF, Hatfield J, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyper-responsiveness in a murine RSV model. Antimicrobial Agents and Chemotherapy. 2004;48:1811-1822
  102. 102. Prince GA, Horswood RL, Camargo E, Koenig D, Chanock RM. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infection and Immunity. 1983;42:81-87
  103. 103. Prince GA, Prieels J-P, Slaoui M, Porter DD. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Laboratory Investigation. 1999;79:1385-1392
  104. 104. Blanco JC, Richardson JY, Narnell ME, Rowzee A, Pletneva L, Porter DD, et al. Cytokine and chemokine gene expresssion after primary and secondary respiratory syncytial virus infection in cotton rats. The Journal of Infectious Diseases. 2002;185:1780-1785
  105. 105. Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a cold passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 1994;12:783-790
  106. 106. Hsu KHL, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus using Ad4, Ad5, Ad7 vectors in dogs and a chimpanzee. The Journal of Infectious Diseases. 1992;166:766-769
  107. 107. Jin H, Cheng X, Train-Dorge VL, Park HJ, Zhou H, Soike K, et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine. 2003;21:3647-3652
  108. 108. Simoes EA, Hayward AR, Ponnuraj EM, Straumanis JP, Stenmark KR, Wilson HL, et al. Respiratory syncytial virus infects the Bonnet monkey, Macaca radiata. Pediatric and Developmental Pathology. 1999;2:316-326
  109. 109. Teng MN, Whithehead SS, Bermingham A, St. Claire M, Elkins WR, Murphy BR, et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. Journal of Virology. 2000;74:9317-9321
  110. 110. Whitehead SS, Bukreyev A, Teng MN, Firestone C-Y, St. Claire M, Elkins WR, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. Journal of Virology. 1999;73:3438-3442
  111. 111. Whitehead SS, Juhasz K, Firestone C-Y, Collins PL, Murphy BR. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. Journal of Virology. 1998;72:4467-4471
  112. 112. Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants and children. The Journal of Infectious Diseases. 1997;176:1428-1436
  113. 113. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunological Reviews. 2011;239:149-166
  114. 114. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among U.S. children, 1980-1995. The Journal of the American Medical Association. 1999;282:1440-1447
  115. 115. Acedo L, Diez-Domingo J, Morano JA, Villanueva RJ. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications. Epidemiology and Infection. 2010;138:853-860
  116. 116. Anderson LJ, Dormitzerb PR, Nokesc DJ, Rappuolie DR, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013;31S:B209-B215
  117. 117. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. The Pediatric Infectious Disease Journal. 2012;31:5-9
  118. 118. Green C, Scarselli E, Sande C, Thompson A, De Lara C, Taylor K, et al. Chimpanzee adenovirusand MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science Translational Medicine. 2015;7:300ra126
  119. 119. Glenn G, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013;31:524-532
  120. 120. Humphreys G. Hubs to spread technology and save lives. Bulletin of the World Health Organization. 2015;93:290-291
  121. 121. DeVincenzo J, Fathi H, McClure M, Westland C, Chanda S, Lambkin-Williams R, et al. Treatment with oral ALS-008176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study. Open Forum Infectious Diseases. 2014;1(Suppl. 1):S66-S69

Written By

Muhammad Shafique, Muhammad Asif Zahoor, Muhammad Imran Arshad, Bilal Aslam, Abu Baker Siddique, Muhammad Hidayat Rasool, Muhammad Usman Qamar and Muhammad Usman

Submitted: 14 November 2018 Reviewed: 29 May 2019 Published: 01 August 2019